SELL and acute graft versus host disease: Although CD62L+ and CD62L- Tregs have been shown to be equally anergic and suppressive upon in vitro stimulation, only the CD62L+ Tregs protect against lethal acute graft-versus-host disease after bone marrow transplantation (27, 28).